This is a phase II, Multi site trial evaluating the efficacy of combination therapy of Bevacizumab (anti-Angiogenesis drug), Atezolizumab (anti PD-L1 drug) and Rucaparib ( PARP inhibitor) with recurrent endometrial cancer
To see combining three drugs, Bevacizumab, Atezolizumab and Rucaparib works well for previously treated recurrent Endometrial Cancer.
St. Luke's University Health Network
Icahn School of Medicine at Mount Sinai
OPEN TO ACCRUAL